» Articles » PMID: 19006678

A Cross-sectional, Mono-centric Pilot Study of Insulin Resistance in Enzyme Replacement Therapy Patients with Gaucher Type I Without Overweight

Overview
Journal Mol Genet Metab
Specialty Endocrinology
Date 2008 Nov 14
PMID 19006678
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Insulin resistance have been demonstrated in untreated patients with Gaucher type I disease. It was implied in overweight enzyme replacement therapy (ERT) treated patients with Gaucher type I disease. In present study we investigate whether insulin resistance is presented in fourteen ERT treated patients with Gaucher type I disease and without overweight in comparison to normal subjects. This work illustrates the presence of insulin resistance in non-overweight ERT treated patients with Gaucher type I disease.

Citing Articles

Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review.

Kaluzna M, Trzeciak I, Ziemnicka K, Machaczka M, Ruchala M Orphanet J Rare Dis. 2019; 14(1):275.

PMID: 31791361 PMC: 6889605. DOI: 10.1186/s13023-019-1211-5.


β-Glycosphingolipids as Mediators of Both Inflammation and Immune Tolerance: A Manifestation of Randomness in Biological Systems.

Ilan Y Front Immunol. 2019; 10:1143.

PMID: 31178868 PMC: 6538797. DOI: 10.3389/fimmu.2019.01143.


Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review.

Doneda D, Netto C, Moulin C, Schwartz I Nutr Metab (Lond). 2013; 10(1):34.

PMID: 23570288 PMC: 3630065. DOI: 10.1186/1743-7075-10-34.


Sphingolipids: the nexus between Gaucher disease and insulin resistance.

Fuller M Lipids Health Dis. 2010; 9:113.

PMID: 20937139 PMC: 2964722. DOI: 10.1186/1476-511X-9-113.